190 related articles for article (PubMed ID: 10984014)
1. A controlled multicenter pediatric study in the treatment of acute respiratory tract diseases with the aid of a new specific compound, erdosteine (IPSE, Italian Pediatric Study Erdosteine).
Titti G; Lizzio A; Termini C; Negri P; Fazzio S; Mancini C
Int J Clin Pharmacol Ther; 2000 Aug; 38(8):402-7. PubMed ID: 10984014
[TBL] [Abstract][Full Text] [Related]
2. Clinical effects of erdosteine in the treatment of acute respiratory tract diseases in children.
Balli F; Bergamini B; Calistru P; Ciofu EP; Domenici R; Doros G; Dragomir D; Gherghina I; Iordachescu F; Murgoci G; Orasanu D; Plesca D; Vaccaro A; Assereto R
Int J Clin Pharmacol Ther; 2007 Jan; 45(1):16-22. PubMed ID: 17256446
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of efficacy and safety of erdosteine in patients affected by chronic bronchitis during an infective exacerbation phase and receiving amoxycillin as basic treatment (ECOBES, European Chronic Obstructive Bronchitis Erdosteine Study).
Marchioni CF; Polu JM; Taytard A; Hanard T; Noseda G; Mancini C
Int J Clin Pharmacol Ther; 1995 Nov; 33(11):612-8. PubMed ID: 8688986
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of erdosteine 900 versus 600 mg/day in reducing oxidative stress in patients with COPD exacerbations: Results of a double blind, placebo-controlled trial.
Dal Negro RW; Visconti M; Turco P
Pulm Pharmacol Ther; 2015 Aug; 33():47-51. PubMed ID: 26116425
[TBL] [Abstract][Full Text] [Related]
5. [Ergoferon liquid dosage form--efficacious and safe treatment for childhood acute respiratory infections. Interim outcomes of a multi-center, randomized, double-blind, placebo-controlled clinical trial].
Geppe NA; Kondiurina EG; Galustian AN; Pak TE; Bal'tserovich NB; Zhiglinskaia OV; Kamaev AV; Lazareva SG; Laléko SL; Mel'nikova IM; Perminova OA; Sabitov AU
Antibiot Khimioter; 2014; 59(5-6):6-14. PubMed ID: 25552038
[TBL] [Abstract][Full Text] [Related]
6. The therapeutic efficacy of erdosteine in the treatment of chronic obstructive bronchitis: a meta-analysis of individual patient data.
Cazzola M; Floriani I; Page CP
Pulm Pharmacol Ther; 2010 Apr; 23(2):135-44. PubMed ID: 19854285
[TBL] [Abstract][Full Text] [Related]
7. Effect of Erdosteine on COPD Exacerbations in COPD Patients with Moderate Airflow Limitation.
Calverley PM; Page C; Dal Negro RW; Fontana G; Cazzola M; Cicero AF; Pozzi E; Wedzicha JA
Int J Chron Obstruct Pulmon Dis; 2019; 14():2733-2744. PubMed ID: 31819405
[TBL] [Abstract][Full Text] [Related]
8. Effect of the mucolytic erdosteine on the success rate of PPI-based first-line triple therapy for Helicobacter pylori eradication: a prospective, double-blind, randomized, placebo-controlled study.
Abut E; Yaşar B; Güveli H; Bölükbaş C; Bölükbaş FF; Dalay AR; Kurdaş OO
Scand J Gastroenterol; 2010 Jun; 45(6):677-83. PubMed ID: 20334478
[TBL] [Abstract][Full Text] [Related]
9. Erdosteine: antitussive and anti-inflammatory effects.
Dal Negro RW
Lung; 2008; 186 Suppl 1():S70-3. PubMed ID: 18185958
[TBL] [Abstract][Full Text] [Related]
10. The effect of long-term treatment with erdosteine on chronic obstructive pulmonary disease: the EQUALIFE Study.
Moretti M; Bottrighi P; Dallari R; Da Porto R; Dolcetti A; Grandi P; Garuti G; Guffanti E; Roversi P; De Gugliemo M; Potena A;
Drugs Exp Clin Res; 2004; 30(4):143-52. PubMed ID: 15553660
[TBL] [Abstract][Full Text] [Related]
11. [ Erdosteine (Mucodox), oral administration].
J Pharm Belg; 2011 Jun; (2):55-6. PubMed ID: 21823444
[No Abstract] [Full Text] [Related]
12. Effect of erdosteine on the rate and duration of COPD exacerbations: the RESTORE study.
Dal Negro RW; Wedzicha JA; Iversen M; Fontana G; Page C; Cicero AF; Pozzi E; Calverley PMA; ;
Eur Respir J; 2017 Oct; 50(4):. PubMed ID: 29025888
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety profile of mucolytic/antioxidant agents in chronic obstructive pulmonary disease: a comparative analysis across erdosteine, carbocysteine, and N-acetylcysteine.
Rogliani P; Matera MG; Page C; Puxeddu E; Cazzola M; Calzetta L
Respir Res; 2019 May; 20(1):104. PubMed ID: 31133026
[TBL] [Abstract][Full Text] [Related]
14. Erdosteine: Drug exhibiting polypharmacy for the treatment of respiratory diseases.
Dal Negro R; Pozzi E; Cella SG
Pulm Pharmacol Ther; 2018 Dec; 53():80-85. PubMed ID: 30352285
[TBL] [Abstract][Full Text] [Related]
15. [Multicenter, controlled, double-blind study of the efficacy and tolerance of Vectrine (erdostein) versus placebo in the treatment of stabilized chronic bronchitis with hypersecretion].
Aubier M; Berdah L
Rev Mal Respir; 1999 Sep; 16(4):521-8. PubMed ID: 10549062
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness of erdosteine, a second generation mucolytic agent, in children with acute rhinosinusitis: a randomized, placebo controlled, double-blinded clinical study.
Unuvar E; Tamay Z; Yildiz I; Toprak S; Kilic A; Aydin S; Kilic G; Guler N; Oguz F; Sidal M
Acta Paediatr; 2010 Apr; 99(4):585-9. PubMed ID: 20055782
[TBL] [Abstract][Full Text] [Related]
17. Erdosteine: its relevance in COPD treatment.
Moretti M
Expert Opin Drug Metab Toxicol; 2009 Mar; 5(3):333-43. PubMed ID: 19331595
[TBL] [Abstract][Full Text] [Related]
18. Influence of erdosteine, a mucolytic agent, on amoxycillin penetration into sputum in patients with an infective exacerbation of chronic bronchitis.
Ricevuti G; Mazzone A; Uccelli E; Gazzani G; Fregnan GB
Thorax; 1988 Aug; 43(8):585-90. PubMed ID: 3051508
[TBL] [Abstract][Full Text] [Related]
19. Erdosteine.
Dechant KL; Noble S
Drugs; 1996 Dec; 52(6):875-81; discussion 882. PubMed ID: 8957158
[TBL] [Abstract][Full Text] [Related]
20. Erdosteine reduces inflammation and time to first exacerbation postdischarge in hospitalized patients with AECOPD.
Moretti M; Fagnani S
Int J Chron Obstruct Pulmon Dis; 2015; 10():2319-25. PubMed ID: 26604731
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
